SPIE Photonics West Digital Forum Showcases Best of Optics, Photonics, Quantum, Biomedical Technologies in Applications and Research
17.3.2021 19:08:00 EET | Business Wire | Press release
SPIE, the international society for optics and photonics, welcomed an engaged global audience to its SPIE Photonics West Digital Forum 6-11 March with 8,000 registered attendees. Across the highly regarded BiOS, LASE, and OPTO symposia, as well as the new industry-focused Quantum West conference, SPIE Photonics West showcased more than 20 plenary speakers, including Ursula Keller, Gérard Mourou, Susumu Noda, Satoshi Kako, Kohji Mitani, Sheila Nirenberg, Laura Fabris, and Yeka Aponte. More than 100 live events – including panel sessions, technical discussions, and networking events complemented the 3,200 on-demand presentations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005651/en/
SPIE Photonics West Digital Forum showcases best of optics, photonics, quantum, biomedical technologies in applications and research (Photo: Business Wire)
In addition, two Digital Marketplaces – one for Photonics West, one for BiOS – together showcased more than 400 exhibitors and over 100 product demonstrations of the latest innovations in optics and photonics.
The largest photonics virtual event of 2021, SPIE Photonics West spotlighted and recognized the best optics and photonics technologies, trends, and entrepreneurial innovations, offering many opportunities for attendees, presenters, scientists, and engineers to engage and discuss their latest research and work. From COVID-focused diagnostics advancements and neuro-technologies to lasers in manufacturing and data center communications, SPIE Photonics West offered a dynamic week of information sharing, learning, and conversation.
Quantum West, a new conference on quantum technology held in partnership with the QED-C, featured industry leaders such as Celia Merzbacher, Peter Knight, Andrew Lord, Wilhelm Kaenders, and Kaitlin Moore exploring the role of photonics in quantum technology’s growth from R&D into engineering products for commercial applications.
"I have worked with SPIE over many years, as both an exhibitor and conference chair, and am very happy to help build Quantum West together with them,” said Quantum West Co-Chair Tim Day who serves as DRS Daylight Solutions GM and senior VP, as well as Member of the Board of ColdQuanta. “SPIE did a great job under challenging circumstances and is always a wonderful partner in terms of bringing the community together and helping to advance photonics technology. We, along with many others in the photonics community, are looking forward to an in-person meeting next January in San Francisco.”
Other industry-focused events featured live sessions with thought leaders discussing today’s hottest application areas, including industrial lasers, sensing and imaging, and autonomous vehicles.
“I come to Photonics West every year with my students,” said Jennifer Barton, who is co-chair for BiOS as well as the director of the University of Arizona’s BIO5 Institute and the university’s Thomas R. Brown Distinguished Professor of Biomedical Engineering. “This year, three of them presented virtually, along with myself. I was very impressed with the high quality of live and prerecorded presentations, the flawless execution of events, and the surprisingly effective opportunities for networking and fun – go Trivia Night! Of course, I am looking forward to seeing everyone in person next year, but I loved how engaging and informative this conference week was.”
“Photonics West is the largest biomedical, laser, and optoelectronic event in our field, even when we cannot travel,” noted SPIE Senior Director of Technical Programs Marilyn Gorsuch. “Given the virtual circumstances, our volunteer conference chairs rolled up their sleeves and produced an amazing offering to present and discuss the latest technical advancements. But nothing can replace the in-person experience and the excitement of gathering together at Photonics West in San Francisco. We are very much looking forward to hosting Photonics West in San Francisco next January.”
All the Photonics West content will be available on the SPIE Digital Library from 20 March.
Photonics West 2022 will take place 22-27 January at the Moscone Center in San Francisco. The Call for Papers will be announced and open in the next few weeks.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005651/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom